Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P31994

UPID:
FCG2B_HUMAN

ALTERNATIVE NAMES:
CDw32; Fc-gamma RII-b

ALTERNATIVE UPACC:
P31994; A6H8N3; O95649; Q53X85; Q5VXA9; Q8NIA1

BACKGROUND:
Low affinity immunoglobulin gamma Fc region receptor II-b, known alternatively as CDw32 and Fc-gamma RII-b, is integral to immune response regulation. It serves as a receptor for immunoglobulins gamma, facilitating key processes such as phagocytosis and antibody production modulation. The receptor's ability to down-modulate cell activation via various pathways underscores its significance in maintaining immune homeostasis.

THERAPEUTIC SIGNIFICANCE:
The receptor's association with systemic lupus erythematosus underscores its potential as a therapeutic target. This chronic autoimmune condition affects various systems, pointing to the receptor's role in immune regulation as a critical area for drug discovery efforts. Exploring the receptor's functions could lead to novel treatments for systemic lupus erythematosus and related autoimmune disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.